Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Operating Expenses (2016 - 2026)

Gyre Therapeutics has reported Operating Expenses over the past 16 years, most recently at $40.8 million for Q4 2025.

  • Quarterly Operating Expenses rose 49.78% to $40.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $106.7 million through Dec 2025, up 21.76% year-over-year, with the annual reading at $105.1 million for FY2025, 17.31% up from the prior year.
  • Operating Expenses was $40.8 million for Q4 2025 at Gyre Therapeutics, up from $23.6 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $124.0 million in Q4 2022 and troughed at -$51.5 million in Q2 2022.
  • The 5-year median for Operating Expenses is $22.4 million (2021), against an average of $28.2 million.
  • The largest YoY upside for Operating Expenses was 444.79% in 2022 against a maximum downside of 344.84% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $22.8 million in 2021, then soared by 444.79% to $124.0 million in 2022, then fell by 1.44% to $122.2 million in 2023, then crashed by 77.73% to $27.2 million in 2024, then skyrocketed by 49.78% to $40.8 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Operating Expenses are $40.8 million (Q4 2025), $23.6 million (Q3 2025), and $23.4 million (Q2 2025).